Case Studies: CASE TWO

Lauren S. Schlesselman, PharmD
Published Online: Wednesday, June 1, 2005

MC presents to her physician's office for a routine checkup. She admits to the physician that she has been experiencing worsening asthma symptoms.

MC has a long history of asthma and congestive heart failure. She is currently taking digoxin 0.125 mg daily. MC is not currently using any medications for her asthma. The physician becomes concerned that MC's digoxin level may be low. He orders a digoxin level and metabolic panel screen. The digoxin level is reported as 0.3 ng/mL. All results in the metabolic panel are within normal limits.

The physician stresses the importance of adhering to her medication therapies. Although MC agrees to take her digoxin, the physician asks her to return in 7 to 10 days for another digoxin level screen. He also starts her on an albuterol inhaler that she can use only when she feels symptomatic.

When the results of the second set of blood work are returned, the digoxin level has increased to 1.0 ng/mL. Unfortunately, MC's serum potassium level is reported as 2.5 mEq/L.

The physician is unsure why MC's potassium level has suddenly dropped. MC denies doing anything differently other than using that "crazy puffer thing for my breathing" and taking her digoxin. What possible cause exists for MC's hypokalemia?

Dr. Schlesselman is a clinical pharmacist based in Niantic, Conn.

Click Here For The Answer -----------> [-]

MC's recent albuterol use is the likely cause of her sudden drop in serum potassium. Albuterol causes potassium to shift from plasma to the intracellular compartment, causing serum levels to decrease. Plasma levels will return to normal if albuterol therapy is discontinued. Unfortunately, MC's risk of digoxin cardiac toxicity is increased with hypokalemia. If she is going to use albuterol routinely, her potassium levels should be monitored closely and treated when levels are extremely low.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues